John Hayslip
About
John Hayslip is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, John Hayslip has authored 29 papers receiving a total of 962 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 10 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in John Hayslip's work include Acute Myeloid Leukemia Research (14 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Neutropenia and Cancer Infections (6 papers). John Hayslip is often cited by papers focused on Acute Myeloid Leukemia Research (14 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Neutropenia and Cancer Infections (6 papers). John Hayslip collaborates with scholars based in United States, Germany and Australia. John Hayslip's co-authors include Andrew H. Wei, Gail J. Roboz, Tara L. Lin, Walter Fiedler, Anoop Enjeti, Kaffa Fakouhi, Brenda Chyla, Roland B. Walter, Stephen A. Strickland and Ahmed Hamed Salem and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.
In The Last Decade
John Hayslip
27 papers receiving 946 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| John Hayslip United States | 14 | 631 | 510 | 206 | 178 | 164 | 29 | 962 | ||
| Juan Eduardo Megías‐Vericat Spain | 16 | 359 0.6× | 230 0.5× | 100 0.5× | 86 0.5× | 164 1.0× | 57 | 654 | ||
| Lisa R. Treviño United States | 8 | 313 0.5× | 457 0.9× | 86 0.4× | 525 2.9× | 259 1.6× | 15 | 1.2k | ||
| Anna Szmigielska‐Kapłon Poland | 16 | 215 0.3× | 198 0.4× | 187 0.9× | 73 0.4× | 151 0.9× | 55 | 570 | ||
| Ernesto Vigna Italy | 15 | 316 0.5× | 296 0.6× | 178 0.9× | 37 0.2× | 193 1.2× | 85 | 649 | ||
| RM Stone United States | 9 | 570 0.9× | 282 0.6× | 123 0.6× | 469 2.6× | 215 1.3× | 13 | 940 | ||
| Abdulkadyrov Km Russia | 11 | 776 1.2× | 391 0.8× | 282 1.4× | 42 0.2× | 417 2.5× | 87 | 996 | ||
| Tomasz Sacha Poland | 14 | 466 0.7× | 175 0.3× | 406 2.0× | 52 0.3× | 134 0.8× | 95 | 727 | ||
| Aleksandra Butrym Poland | 15 | 241 0.4× | 274 0.5× | 112 0.5× | 33 0.2× | 133 0.8× | 58 | 645 | ||
| Nicoletta Crescenzio Italy | 16 | 197 0.3× | 245 0.5× | 87 0.4× | 42 0.2× | 124 0.8× | 33 | 663 | ||
| E. Winton United States | 13 | 403 0.6× | 112 0.2× | 88 0.4× | 134 0.8× | 148 0.9× | 23 | 608 |
Countries citing papers authored by John Hayslip
Since
Specialization
Citations
This map shows the geographic impact of John Hayslip's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Hayslip with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Hayslip more than expected).
Fields of papers citing papers by John Hayslip
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by John Hayslip. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Hayslip. The network helps show where John Hayslip may publish in the future.
Co-authorship network of co-authors of John Hayslip
This figure shows the co-authorship network connecting the top 25 collaborators of John Hayslip. A scholar is included among the top collaborators of John Hayslip based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Hayslip. John Hayslip is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Zhang, Yanni, Jie Xia, Chunyan Ye, et al.. (2022). Exploration of the Therapeutic Effects of CD47 and CD38 Antibody Combination in Relapsed or Refractory Multiple Myeloma (rrMM) and the Correlation with CD47 and CD38 Expression. Blood. 140(Supplement 1). 9937–9938.
2.
Vos, Sven de, John P. Leonard, Jonathan W. Friedberg, et al.. (2020). Safety and efficacy of navitoclax, a BCL-2 and BCL-X L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. Leukemia & lymphoma. 62(4). 810–818.
3.
Brackman, Deanna J., Rajeev Menon, Ahmed Hamed Salem, et al.. (2020). Venetoclax Exposure-Efficacy and Exposure-Safety Relationships in Subjects with Treatment-Naïve Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy. Blood. 136(Supplement 1). 52–52.
4.
Wei, Andrew H., Stephen A. Strickland, Jing-Zhou Hou, et al.. (2019). Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology. 37(15). 1277–1284.
5.
Agarwal, Suresh, Sathej Gopalakrishnan, Sven Mensing, et al.. (2019). Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure‐response analysis. Hematological Oncology. 37(4). 464–473.
6.
Pratz, Keith W., Courtney D. DiNardo, Martha Arellano, et al.. (2019). Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies. Blood. 134(Supplement_1). 264–264.
7.
Chyla, Brenda, Jason G. Harb, Christine Mantis, et al.. (2019). Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression. Blood. 134(Supplement_1). 546–546.
8.
Saeed, Hayder, et al.. (2016). Oxidative Stress Following High Dose Chemotherapy with Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation. 22(3). S131–S132.
9.
Chyla, Brenda, Relja Popovic, Jalaja Potluri, et al.. (2016). Correlative Biomarkers of Response to Venetoclax in Combination with Chemotherapy or Hypomethylating Agents in Elderly Untreated Patients with Acute Myeloid Leukemia. Blood. 128(22). 1709–1709.
10.
Hayslip, John, Emily V. Dressler, Heidi L. Weiss, et al.. (2015). Plasma TNF-α and Soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna—A Randomized, Cross-Over Clinical Study. PLoS ONE. 10(4). e0124988–e0124988.
11.
Ahmed, Tamer A., John Hayslip, & Markos Leggas. (2014). Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition. Leukemia Research. 38(11). 1350–1357.
12.
Howard, Dianna S., Jane L. Liesveld, Gordon L. Phillips, et al.. (2013). A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. Leukemia Research. 37(11). 1502–1508.
13.
Ahmed, Tamer A., John Hayslip, & Markos Leggas. (2013). Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients. Cancer Chemotherapy and Pharmacology. 72(6). 1369–1374.
14.
Kelly, Kevin R., Daniel O. Persky, Daruka Mahadevan, et al.. (2013). Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas. Blood. 122(21). 3027–3027.
15.
Ahmed, Tamer A., Jamie Horn, John Hayslip, & Markos Leggas. (2012). Validated LC–MS/MS method for simultaneous determination of SIM and its acid form in human plasma and cell lysate: Pharmacokinetic application. Journal of Pharmaceutical Analysis. 2(6). 403–411.
16.
Ahmed, Tamer A., John Hayslip, & Markos Leggas. (2012). Abstract 3778: Pharmacokinetic, safety and efficacy of high dose simvastatin in refractory and relapsed chronic lymphocytic leukemia (CLL) patients. Cancer Research. 72(8_Supplement). 3778–3778.
17.
Hayslip, John, Uzair B. Chaudhary, Mark A. Green, et al.. (2007). Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer. 7(1). 221–221.
18.
Hayslip, John & Robert S. Fenning. (2007). Safe Administration of Iodine-131 Tositumomab After Repeated Infusion-Related Reactions to Rituximab. The Oncologist. 12(3). 338–340.
19.
McDonnell, Anne, et al.. (2006). Single‐Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 26(6). 806–812.
20.
Hayslip, John & Alberto J. Montero. (2006). Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review.. Molecular Cancer. 5(1). 44–44.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Juan Eduardo Megías‐Vericat Breakdown of academic impact, for papers by Lisa R. Treviño Breakdown of academic impact, for papers by Anna Szmigielska‐Kapłon Breakdown of academic impact, for papers by Ernesto Vigna Breakdown of academic impact, for papers by RM Stone Breakdown of academic impact, for papers by Abdulkadyrov Km Breakdown of academic impact, for papers by Tomasz Sacha Breakdown of academic impact, for papers by Aleksandra Butrym Breakdown of academic impact, for papers by Nicoletta Crescenzio Breakdown of academic impact, for papers by E. Winton